In the second, a separate network meta-analysis of 22 trials with 143,153 participants without diabetes at study outset, ARBs and ACE inhibitors were associated with the lowest proportion of subjects developing diabetes during clinical trial follow-up compared with other classes of antihypertensive agents (odds ratio, 0.57 for ARBs, p< 0.0001; and 0.67 for ACE inhibitors, p< 0.0001, using initial diuretic therapy as a standard of comparison) (50). This evidence concerns the gene ACE and diabetes mellitus.